Advertisement
IQV vs SYK
Which Stock Would AI Choose? IQVIA Holdings Inc. (IQV) vs. Stryker Corporation (SYK) Stock Comparison
Key Takeaways
- IQV trades at a lower PE ratio (price-to-earnings) of 20.87 compared to SYK's 39.21, suggesting relative value in healthcare services.
- SYK exhibits lower volatility with a beta of 0.93 versus IQV's 1.39, appealing to stability-focused investors.
- Recent market activity shows IQV underperforming with YTD declines around 27%, while SYK holds steadier at about 7% YTD drop.
- Both stocks face sector headwinds, but SYK's larger market cap of $126B provides scale advantages over IQV's $27.5B.
- Upcoming earnings for both could shift sentiment, with SYK on April 30 and IQV on May 5.
Introduction
IQV and SYK represent distinct facets of the healthcare sector: IQVIA Holdings Inc. focuses on analytics, technology, and clinical research services for life sciences, while Stryker Corporation specializes in medical devices across orthopaedics, neurotechnology, and MedSurg. This stock comparison is relevant for investors seeking exposure to healthcare innovation amid evolving market conditions, including AI advancements and operational challenges. Traders monitoring relative performance may find insights into momentum, valuation, and risk profiles valuable for position sizing or sector rotation strategies in a volatile environment.
IQV Overview and Recent Performance
IQVIA Holdings Inc. (IQV) is a global leader in advanced analytics, technology solutions, and clinical research services for the life sciences industry, serving pharmaceutical, biotech, and medtech clients. In recent market activity, the stock has traded around $163-164, down significantly from its 52-week high of $247 amid broader healthcare pressures. YTD performance reflects approximately 27% declines, with 1-month returns around -1.5% and sharper 3-month drops. Sentiment has been influenced by in-line Q4 results, a new IQVIA.ai platform launch with NVIDIA, and AI-related valuation concerns, alongside upcoming Q1 earnings on May 5. Higher beta of 1.39 underscores volatility tied to clinical trial and biotech funding trends.
SYK Overview and Recent Performance
Stryker Corporation (SYK) is a medical technology firm offering products in orthopaedics, MedSurg, and neurotechnology, impacting patient outcomes worldwide. Shares recently closed near $329, within a 52-week range of $319-$405, with market cap at $126 billion. Recent weeks show modest YTD declines of about 7%, with 1-month stability around flat to -1%. Key influences include a recent cyberattack highlighting resilience needs, strong historical organic growth of 10.2% over two years, and anticipation for Q1 earnings on April 30 expecting $2.98 EPS and $6.29B revenue. Lower beta of 0.93 reflects relative stability in device demand.
Trending AI Robots
Tickeron's Trending AI Robots page showcases the platform's top-performing AI trading bots, curated from hundreds available that trade thousands of tickers across stocks, ETFs, and crypto. Out of 351 total bots, 25 are highlighted as best suited for current market conditions, featuring diverse strategies like pattern recognition, swing trading, and long-term trends with varying timeframes from intraday to multi-week holds. These bots display key stats such as win rates, profit factors, Sharpe ratios, and max drawdowns to aid copy trading decisions. Traders can explore bots optimized for healthcare volatility or device sector momentum. Visit the Trending AI Robots page to evaluate real-time performers and align with your risk profile.
Head-to-Head Comparison
IQV and SYK both operate in healthcare but diverge in business models: IQV's service-oriented analytics contrast SYK's tangible device manufacturing, exposing IQV more to biotech funding cycles and SYK to procedural volumes and supply chain risks. Growth drivers include IQV's AI integrations like IQVIA.ai versus SYK's orthopaedics expansion; recent momentum favors SYK's steadier returns over IQV's pullbacks. Risk factors highlight IQV's higher beta and valuation fears against SYK's cyber disruptions. Sector exposure ties both to medtech, but SYK benefits from scale. Market sentiment leans cautiously optimistic for SYK pre-earnings, while IQV grapples with AI hype cooldowns.
Tickeron AI Verdict
Tickeron's AI currently leans toward SYK with higher probability for near-term outperformance, driven by trend consistency, lower volatility, robust historical growth, and positive earnings setup relative to IQV's recent declines and sentiment pressures. This positioning reflects observable stability and catalysts in a choppy healthcare landscape.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IQV is a Hold and SYK is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
IQV’s FA Score shows that 0 FA rating(s) are green whileSYK’s FA Score has 1 green FA rating(s).
- IQV’s FA Score: 0 green, 5 red.
- SYK’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
IQV’s TA Score shows that 5 TA indicator(s) are bullish while SYK’s TA Score has 4 bullish TA indicator(s).
- IQV’s TA Score: 5 bullish, 4 bearish.
- SYK’s TA Score: 4 bullish, 3 bearish.
Price Growth
IQV (@Medical Specialties) experienced а -7.34% price change this week, while SYK (@Medical/Nursing Services) price change was +0.71% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was -1.17%. For the same industry, the average monthly price growth was +8.92%, and the average quarterly price growth was -2.29%.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was +23.45%. For the same industry, the average monthly price growth was +12.35%, and the average quarterly price growth was -13.81%.
Reported Earning Dates
IQV is expected to report earnings on Jul 28, 2026.
SYK is expected to report earnings on Jul 30, 2026.
Industries' Descriptions
@Medical Specialties (-1.17% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
@Medical/Nursing Services (+23.45% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
| IQV | SYK | IQV / SYK | |
| Capitalization | 28B | 118B | 24% |
| EBITDA | 3.52B | 6.44B | 55% |
| Gain YTD | -25.571 | -12.188 | 210% |
| P/E Ratio | 20.84 | 35.63 | 59% |
| Revenue | 16.6B | 25.3B | 66% |
| Total Cash | 2.1B | 2.97B | 71% |
| Total Debt | 16.1B | 14.7B | 110% |
IQV | SYK | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 64 | 72 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 58 Fair valued | 9 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 67 | |
SMR RATING 1..100 | 42 | 57 | |
PRICE GROWTH RATING 1..100 | 60 | 62 | |
P/E GROWTH RATING 1..100 | 54 | 80 | |
SEASONALITY SCORE 1..100 | 90 | 41 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
SYK's Valuation (9) in the Medical Specialties industry is somewhat better than the same rating for IQV (58) in the Servicestothe Health Industry industry. This means that SYK’s stock grew somewhat faster than IQV’s over the last 12 months.
SYK's Profit vs Risk Rating (67) in the Medical Specialties industry is somewhat better than the same rating for IQV (100) in the Servicestothe Health Industry industry. This means that SYK’s stock grew somewhat faster than IQV’s over the last 12 months.
IQV's SMR Rating (42) in the Servicestothe Health Industry industry is in the same range as SYK (57) in the Medical Specialties industry. This means that IQV’s stock grew similarly to SYK’s over the last 12 months.
IQV's Price Growth Rating (60) in the Servicestothe Health Industry industry is in the same range as SYK (62) in the Medical Specialties industry. This means that IQV’s stock grew similarly to SYK’s over the last 12 months.
IQV's P/E Growth Rating (54) in the Servicestothe Health Industry industry is in the same range as SYK (80) in the Medical Specialties industry. This means that IQV’s stock grew similarly to SYK’s over the last 12 months.
| IQV | SYK | |
|---|---|---|
| RSI ODDS (%) | N/A | N/A |
| Stochastic ODDS (%) | 3 days ago 67% | 3 days ago 60% |
| Momentum ODDS (%) | 3 days ago 67% | 3 days ago 52% |
| MACD ODDS (%) | 3 days ago 55% | 3 days ago 59% |
| TrendWeek ODDS (%) | 3 days ago 64% | 3 days ago 54% |
| TrendMonth ODDS (%) | 3 days ago 69% | 3 days ago 52% |
| Advances ODDS (%) | 12 days ago 58% | 16 days ago 55% |
| Declines ODDS (%) | 3 days ago 65% | 10 days ago 53% |
| BollingerBands ODDS (%) | 3 days ago 61% | 3 days ago 81% |
| Aroon ODDS (%) | 3 days ago 44% | 3 days ago 44% |
Advertisement
IQV and
Correlation & Price change
A.I.dvisor indicates that over the last year, IQV has been closely correlated with CRL. These tickers have moved in lockstep 75% of the time. This A.I.-generated data suggests there is a high statistical probability that if IQV jumps, then CRL could also see price increases.
| Ticker / NAME | Correlation To IQV | 1D Price Change % | ||
|---|---|---|---|---|
| IQV | 100% | -1.70% | ||
| CRL - IQV | 75% Closely correlated | +1.46% | ||
| TMO - IQV | 71% Closely correlated | +0.63% | ||
| MEDP - IQV | 69% Closely correlated | +0.68% | ||
| RVTY - IQV | 65% Loosely correlated | +2.23% | ||
| A - IQV | 63% Loosely correlated | +2.20% | ||
More | ||||
SYK and
Correlation & Price change
A.I.dvisor indicates that over the last year, SYK has been loosely correlated with ISRG. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if SYK jumps, then ISRG could also see price increases.